Signet Therapeutics, a pioneering biopharmaceutical company in China specializing in cancer targeted therapies based on organoid disease models and artificial intelligence (AI), has entered into a strategic partnership with Guangzhou Jennio Biotech Co., Ltd. The collaboration aims to leverage organoid disease models and advance tumor immunotherapy drug development. Financial specifics of the agreement were not disclosed.
As the world’s first developer of cancer targeted therapies utilizing organoid disease models and AI, Signet Therapeutics has established a proprietary platform that has led to significant advancements in research for diffuse gastric cancer, ovarian cancer, triple negative breast cancer, and other hard-to-treat diseases. The company has successfully transitioned its lead pipeline, sigx1094, which targets diffuse gastric cancer, into clinical trials. Jennio Bio, recognized as a Contract Research Organization (CRO) specializing in tumor immunotherapy, boasts an extensive PDX tumor specimen bank, a primary cell bank, and a diverse array of animal model resources for various diseases. – Flcube.com
